Register for our free email digests:
Intellectual Property
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
H2 Pharma Offloads Minority Interest To Private Equity
H2 Pharma, which specializes in both generic and OTC liquid formulations, is looking to climb to the next level after receiving an equity investment from Ardian.
Hikma Eyes Another Hybrid Injectable With Arecor
London-listed Hikma has signed a second partnership agreement with Arecor, proposing to co-develop a 505(b)(2) hybrid injectable product for the US market.
Shilpa Hit With FDA Warning Letter
India’s Shilpa Medicare has received a warning letter from the US FDA for its finished dosage formulation facility in Jadcherla, Telangana. The company has insisted that supplies from the facility will not be disrupted while it engages with the FDA to resolve the issues.
Teva Gets EU Backing For OTC Desloratadine
Teva subsidiary Ratiopharm has secured EMA backing for the EU-wide switch of allergy drug desloratadine.
Zentiva Continues European Endeavors With Greek Partnership
Zentiva has struck a new partnership to expand its already significant operations in Europe, this time in Greece with local firm Lavipharm.
Awards Offers Two Weeks Of Online Networking
From 20 October, a free online platform will allow registrants attending the digital Global Generics & Biosimilars Awards 2020 to participate in two weeks of dedicated networking activities ahead of the ceremony on 3 November.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.